Literature DB >> 31501262

The Immune Microenvironment and Cancer Metastasis.

Asmaa El-Kenawi1, Kay Hänggi1, Brian Ruffell1,2.   

Abstract

The dynamic interplay between neoplastic cells and the immune microenvironment regulates every step of the metastatic process. Immune cells contribute to invasion by secreting a cornucopia of inflammatory factors that promote epithelial-to-mesenchymal transition and remodeling of the stroma. Cancer cells then intravasate to the circulatory system assisted by macrophages and use several pathways to avoid recognition by cytotoxtic lymphocytes and phagocytes. Circulating tumor cells that manage to adhere to the vasculature and encounter premetastic niches are able to use the associated myeloid cells to extravasate into ectopic organs and establish a dormant microscopic colony. If successful at avoiding repetitive immune attack, dormant cells can subsequently grow into overt, clinically detectable metastatic lesions, which ultimately account to most cancer-related deaths. Understanding how disseminated tumor cells evade and corrupt the immune system during the final stages of metastasis will be pivotal in developing new therapeutic modalities that combat metastasis.
Copyright © 2020 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 31501262      PMCID: PMC7117953          DOI: 10.1101/cshperspect.a037424

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  232 in total

Review 1.  Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.

Authors:  Peter J Chockley; Venkateshwar G Keshamouni
Journal:  J Immunol       Date:  2016-08-01       Impact factor: 5.422

2.  Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice.

Authors:  Jean Albrengues; Mario A Shields; David Ng; Chun Gwon Park; Alexandra Ambrico; Morgan E Poindexter; Priya Upadhyay; Dale L Uyeminami; Arnaud Pommier; Victoria Küttner; Emilis Bružas; Laura Maiorino; Carmelita Bautista; Ellese M Carmona; Phyllis A Gimotty; Douglas T Fearon; Kenneth Chang; Scott K Lyons; Kent E Pinkerton; Lloyd C Trotman; Michael S Goldberg; Johannes T-H Yeh; Mikala Egeblad
Journal:  Science       Date:  2018-09-28       Impact factor: 47.728

3.  Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro.

Authors:  R B Wesley; X Meng; D Godin; Z S Galis
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-03       Impact factor: 8.311

4.  Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03.

Authors:  Satoshi Teramukai; Toshiyuki Kitano; Yusuke Kishida; Masaaki Kawahara; Kaoru Kubota; Kiyoshi Komuta; Koichi Minato; Tadashi Mio; Yuka Fujita; Toshiro Yonei; Kikuo Nakano; Masahiro Tsuboi; Kazuhiko Shibata; Kiyoyuki Furuse; Masanori Fukushima
Journal:  Eur J Cancer       Date:  2009-02-21       Impact factor: 9.162

5.  Matrix architecture dictates three-dimensional migration modes of human macrophages: differential involvement of proteases and podosome-like structures.

Authors:  Emeline Van Goethem; Renaud Poincloux; Fabienne Gauffre; Isabelle Maridonneau-Parini; Véronique Le Cabec
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

6.  Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.

Authors:  Christine Pasero; Gwenaëlle Gravis; Mathilde Guerin; Samuel Granjeaud; Jeanne Thomassin-Piana; Palma Rocchi; Maria Paciencia-Gros; Flora Poizat; Mélanie Bentobji; Francine Azario-Cheillan; Jochen Walz; Naji Salem; Serge Brunelle; Alessandro Moretta; Daniel Olive
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

7.  Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.

Authors:  Etienne Meylan; Alison L Dooley; David M Feldser; Lynn Shen; Erin Turk; Chensi Ouyang; Tyler Jacks
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962

8.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

9.  Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2Rγ(null) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis.

Authors:  Chloe C Milsom; Christina R Lee; Christina Hackl; Shan Man; Robert S Kerbel
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

10.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.

Authors:  Nicholas McGranahan; Rachel Rosenthal; Crispin T Hiley; Andrew J Rowan; Thomas B K Watkins; Gareth A Wilson; Nicolai J Birkbak; Selvaraju Veeriah; Peter Van Loo; Javier Herrero; Charles Swanton
Journal:  Cell       Date:  2017-10-26       Impact factor: 41.582

View more
  24 in total

Review 1.  Oxidative Stress in Cancer.

Authors:  John D Hayes; Albena T Dinkova-Kostova; Kenneth D Tew
Journal:  Cancer Cell       Date:  2020-07-09       Impact factor: 31.743

2.  MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma.

Authors:  Ravikanth Maddipati; Robert J Norgard; Timour Baslan; Komal S Rathi; Amy Zhang; Asal Saeid; Taku Higashihara; Feng Wu; Angad Kumar; Valli Annamalai; Saurav Bhattacharya; Pichai Raman; Christian A Adkisson; Jason R Pitarresi; Maximilian D Wengyn; Taiji Yamazoe; Jinyang Li; David Balli; Michael J LaRiviere; Tuong-Vi C Ngo; Ian W Folkert; Ian D Millstein; Jonathan Bermeo; Erica L Carpenter; John C McAuliffe; Maja H Oktay; Rolf A Brekken; Scott W Lowe; Christine A Iacobuzio-Donahue; Faiyaz Notta; Ben Z Stanger
Journal:  Cancer Discov       Date:  2021-09-22       Impact factor: 38.272

3.  A Novel lncRNA Panel for Risk Stratification and Immune Landscape in Breast Cancer Patients.

Authors:  Chen Li; Xiaolong Wang; Tong Chen; Wenhao Li; Qifeng Yang
Journal:  Int J Gen Med       Date:  2022-05-27

4.  Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer.

Authors:  Yuko Kumagai; Yurie Futoh; Hideyo Miyato; Hideyuki Ohzawa; Hironori Yamaguchi; Shin Saito; Kentaro Kurashina; Yoshinori Hosoya; Alan Kawarai Lefor; Naohiro Sata; Joji Kitayama
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

5.  Analysis of the prognostic role and biological characteristics of circulating tumor cell-associated white blood cell clusters in non-small cell lung cancer.

Authors:  Zheng Li; Liwen Fan; Yun Wu; Yuxu Niu; Xuelin Zhang; Bin Wang; Yuanshan Yao; Chunji Chen; Ning Qi; Daisy Dandan Wang; Peter Ping Lin; Dongfang Tang; Wen Gao
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

6.  A Comprehensive Pan-Cancer Analysis of the Tumorigenic Role of Matrix Metallopeptidase 7 (MMP7) Across Human Cancers.

Authors:  Nana Meng; Yaguang Li; Pengcheng Jiang; Xuefeng Bu; Jifei Ding; Yan Wang; Xiaodong Zhou; Feng Yu; Yongjun Zhang; Jie Zhang; Leizhou Xia
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

7.  Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer.

Authors:  Xiangmei Zhang; Jingping Li; Qing Yang; Yanfang Wang; Xinhui Li; Yunjiang Liu; Baoen Shan
Journal:  Ann Transl Med       Date:  2020-09

8.  Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas.

Authors:  Lauren H Boal; John Glod; Melissa Spencer; Miki Kasai; Joanne Derdak; Eva Dombi; Mark Ahlman; Daniel W Beury; Melinda S Merchant; Christianne Persenaire; David J Liewehr; Seth M Steinberg; Brigitte C Widemann; Rosandra N Kaplan
Journal:  Clin Cancer Res       Date:  2020-09-17       Impact factor: 13.801

9.  CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression.

Authors:  Meiling Zhang; Zongzhi Z Liu; Keisuke Aoshima; Wesley L Cai; Hongyin Sun; Tianrui Xu; Yangyi Zhang; Yongyan An; Jocelyn F Chen; Lok Hei Chan; Asako Aoshima; Sabine M Lang; Zhenwei Tang; Xuanlin Che; Yao Li; Sara J Rutter; Veerle Bossuyt; Xiang Chen; Jon S Morrow; Lajos Pusztai; David L Rimm; Mingzhu Yin; Qin Yan
Journal:  Sci Transl Med       Date:  2022-02-02       Impact factor: 19.319

10.  Preoperative Blood Inflammatory Markers for the Differentiation of Uterine Leiomyosarcoma from Leiomyoma.

Authors:  Dong Soo Suh; Yong Jung Song; Hyun-Jin Roh; Sang Hun Lee; Dae Hoon Jeong; Tae Hwa Lee; Kyung Un Choi; Ki Hyung Kim
Journal:  Cancer Manag Res       Date:  2021-06-24       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.